scholarly journals Direct Regulation of Prostate Blood Flow by Vascular Endothelial Growth Factor and Its Participation in the Androgenic Regulation of Prostate Blood Flow in Vivo

Endocrinology ◽  
2004 ◽  
Vol 145 (10) ◽  
pp. 4507-4512 ◽  
Author(s):  
Yasuhiro Shibata ◽  
Bunzo Kashiwagi ◽  
Seiji Arai ◽  
Yoshitatsu Fukabori ◽  
Kazuhiro Suzuki ◽  
...  

Abstract Previous studies on prostate blood flow regulation have indicated that androgen regulates prostate blood flow. However, the mechanism responsible for this regulation is unknown. In the present study, we focused on the effects of vascular endothelial growth factor (VEGF), a key factor responsible for angiogenesis and androgenic blood flow regulation. We examined in vivo the effect of VEGF on prostate blood flow and its participation in the androgenic regulation of this blood flow using a castrated rat model following subcapsular intraprostatic injection method. We found that VEGF is involved in blood flow regulation with an activity equal to that of dihydrotestosterone (DHT). The effect of VEGF on prostate blood flow was already seen at 30 min after the administration. The elevating effect of DHT on castrated rat prostate blood flow was abolished by coadministration of DHT with neutralizing anti-VEGF antibody. The change in VEGF-A mRNA expression in response to androgen stimulation was examined by double-fluorescent probe quantitative PCR (Taqman PCR). The results showed that androgenic regulation of VEGF gene expression occurred shortly after androgen stimulation. VEGF gene up-regulation was abolished or down-regulated by coadministration of neutralizing anti-VEGF antibody. This is the first report on the importance of VEGF in the androgenic regulation signaling pathway that affects prostate blood flow. Alternative treatment targeted toward anti-VEGF activity as a substitute for ordinary antiandrogenic therapy may be effective against prostate diseases, especially those with androgen-independent and hyperhemorrhagic status.

Urology ◽  
2006 ◽  
Vol 68 (5) ◽  
pp. 1127-1131 ◽  
Author(s):  
Yasuhiro Shibata ◽  
Bunzo Kashiwagi ◽  
Seiji Arai ◽  
Tomohiro Magari ◽  
Kazuhiro Suzuki ◽  
...  

Blood ◽  
2010 ◽  
Vol 116 (11) ◽  
pp. 1980-1989 ◽  
Author(s):  
Monika Edelbauer ◽  
Dipak Datta ◽  
Ingrid H. C. Vos ◽  
Aninda Basu ◽  
Maria P. Stack ◽  
...  

Abstract In these studies, we find that the vascular endothelial growth factor (VEGF) receptor KDR is expressed on subsets of mitogen-activated CD4+ and CD8+ T cells in vitro. We also found that KDR colocalizes with CD3 on mitogen-activated T cells in vitro and on infiltrates within rejecting human allografts in vivo. To evaluate whether VEGF and KDR mediate lymphocyte migration across endothelial cells (ECs), we used an in vitro live-time transmigration model and observed that both anti-VEGF and anti-KDR antibodies inhibit the transmigration of both CD4+ and CD8+ T cells across tumor necrosis factorα (TNFα)–activated, but not unactivated ECs. In addition, we found that interactions among CD4+ or CD8+ T cells and TNFα–activated ECs result in the induction of KDR on each T cell subset, and that KDR-expressing lymphocytes preferentially transmigrate across TNFα–activated ECs. Finally, using a humanized severe combined immunodeficient mouse model of lymphocyte trafficking, we found that KDR-expressing lymphocytes migrate into human skin in vivo, and that migration is reduced in mice treated with a blocking anti-VEGF antibody. These observations demonstrate that induced expression of KDR on subsets of T cells, and locally expressed VEGF, facilitate EC-dependent lymphocyte chemotaxis, and thus, the localization of T cells at sites of inflammation.


Sign in / Sign up

Export Citation Format

Share Document